Rimantadine-Darnitsa 50 mg tablets, No. 20 (10 x 2)

In stock: 6
$32.40

Ingredients

Active ingredient: rimantadine;

1 tablet contains 50 mg of rimantadine hydrochloride;

Excipients: lactose monohydrate, corn starch, povidone, colloidal anhydrous silicon dioxide, magnesium stearate.

Dosage Form

Tablets.

Main physical and chemical properties: white or white tablets with a yellowish tint, flat-cylindrical in shape, with a bevel and a score line.

Pharmacotherapeutic group

Antiviral agents for systemic use. Cyclic amines.

ATC code J05A C02.

Pharmacological properties

Pharmacodynamics.

Rimantadine hydrochloride is a derivative of amantadine and possesses pronounced antiviral activity. It is effective against various influenza A viruses and also exerts an antitoxic effect in influenza caused by the type B virus. Rimantadine inhibits viral replication in the early stages of the cycle by disrupting the formation of the viral envelope. Genetic experiments have shown that a specific protein of the M2 gene of the virion plays a major role in rimantadine’s antiviral activity against the influenza A virus.  In vitro, rimantadine inhibits the replication of all three antigenic subtypes (H1, N1, H2N2, H3N3) of the influenza virus found in humans.Rimantadine does not affect the immunogenic properties of the inactivated influenza A vaccine.

Rimantadine-Darnitsa is also effective against arboviruses, which are the causative agents of tick-borne encephalitis.

Pharmacokinetics.

Following single and multiple doses of the drug in patients of different age groups, no correlation has been established between the concentration of rimantadine in blood plasma and its antiviral activity.

After oral administration, the drug is almost completely absorbed. Absorption is slow. Plasma protein binding is approximately 40%. Volume of distribution: 17–25 L/kg in adults, 289 L/kg in children. The concentration in nasal secretions is 50% higher than in plasma. The maximum plasma concentration of the active ingredient at a dose of 100 mg once daily is 181 ng/mL; at 100 mg twice daily, it is 416 ng/mL.

It is metabolized in the liver. The half-life is 24–36 hours. 75–85% of the dose is excreted by the kidneys, primarily as metabolites, and 15% is excreted unchanged.

In chronic renal failure, the half-life doubles. In patients with renal failure and in the elderly, the concentration of the active ingredient may increase to toxic levels.

For patients with chronic liver disease, particularly compensated cirrhosis, no dose reduction is required, as the pharmacokinetics following a single 200-mg dose do not differ significantly from those in healthy individuals. However, in patients with severe hepatic insufficiency, at a dose of 200 mg, the AUC is 3 times higher, the half-life is 2 times longer, and clearance is 50% lower compared to healthy adults with normal liver function.

The pharmacokinetic profile of rimantadine in children is similar to that in healthy adults.

Indications

Early treatment of influenza A virus infection in adults and children 10 years of age and older.

Prevention of influenza A during an epidemic in adults and children 10 years of age and older.

Contraindications

Hypersensitivity to rimantadine, adamantane derivatives, or the drug’s excipients.

Acute and chronic liver and kidney diseases.

Thyrotoxicosis.

Drug Interactions and Other Interactions

Urine-alkalizing agents (acetazolamide, sodium bicarbonate) and cimetidine increase the plasma concentration of rimantadine.

Urine acidifiers (ammonium chloride, ascorbic acid), paracetamol, and acetylsalicylic acid reduce the effectiveness of rimantadine.

Rimantadine reduces the effectiveness of antiepileptic drugs and enhances the stimulating effect of caffeine.

During treatment, patients should refrain from consuming alcoholic beverages, as this may cause adverse reactions affecting the central nervous system.

Special Considerations

The maximum therapeutic effect is achieved when the drug is administered within the first 2 days of the onset of the illness.

Rimantadine should be prescribed with caution to patients with gastrointestinal disorders, liver dysfunction, severe heart disease, and arrhythmias, as well as to the elderly. In these cases, a reduced dose is recommended.

In patients with a history of epilepsy and anticonvulsant therapy, the risk of a seizure increases with the use of rimantadine. In this case, the dose should be reduced to 100 mg per day. If a seizure occurs, the medication should be discontinued.

Drug-resistant viruses may develop.

During treatment, patients should refrain from consuming alcoholic beverages, as this may cause undesirable side effects affecting the central nervous system.

Rimantadine-Darnitsa contains lactose; therefore, patients with rare hereditary forms of galactose intolerance, lactase deficiency, or glucose-galactose malabsorption should not take this medication.

Pregnancy and lactation.

Rimantadine-Darnitsa should not be used during pregnancy. If use of the drug is necessary, breastfeeding should be discontinued.

Effects on the ability to drive and operate machinery.

While using this medication, patients should refrain from driving or operating potentially hazardous machinery.

Dosage and Administration

Take the tablets orally after meals with water.

Treatment should begin as early as possible, immediately after the first symptoms of the flu appear. The therapeutic effect is more pronounced if treatment is started within the first 48 hours after the onset of the first flu symptoms.

Treatment of the flu: for adults and children over 10 years of age: 100 mg (2 tablets) twice daily.

Be sure to consult a doctor before giving this medication to children.

For elderly patients (over 65 years of age)—100 mg (2 tablets) once daily.

The duration of treatment is 5 days.

Flu prevention: For adults and children over 10 years of age: 100 mg (2 tablets) twice daily.

For elderly patients or those at high risk of complications: 100 mg (2 tablets) once daily.

Treatment should begin at the start of the flu season and continue throughout the season, but for no longer than 2 weeks.

Children.

Rimantadine-Darnitsa should be used in children over 10 years of age.

Overdose

In cases of overdose, symptomatic treatment should be administered to support vital bodily functions.

There is a reported case of poisoning with a chemical analog—amantadine.

Symptoms: agitation, hallucinations, cardiac arrhythmias, fever, chills, sweating, arrhythmia, hypoesthesia, increased tearing, dysphagia, constipation, frequent urination, stomatitis, eye pain.

Treatment: discontinuation of the drug, gastric lavage, intravenous administration of physostigmine; for children and adults, the initial dose is 0.5 mg; repeat administration if necessary, but not to exceed 2 mg within 1 hour. Rimantadine and amantadine are not removed by hemodialysis.

Side Effects

Side effects usually disappear after discontinuation of the drug.

Sensory organs: altered or lost sense of taste, parosmia.

Hearing and vestibular disorders: tinnitus.

Respiratory, thoracic, and mediastinal disorders: cough, shortness of breath (dyspnea), bronchospasm.

Gastrointestinal system: dyspepsia, nausea, vomiting, dry mouth, abdominal pain, diarrhea, indigestion, anorexia.

Nervous system disorders: headache, dizziness, tremor, ataxia (impaired coordination), hyperkinesia (spontaneous movements), seizures, insomnia, excessive fatigue, drowsiness, impaired concentration, confusion, hyperactivity, nervousness, anxiety, depression, euphoria, hallucinations.

Cardiovascular disorders: rapid heartbeat, tachycardia, hypertension, cerebrovascular disorders, heart failure, edema, cardiac conduction disturbances (blocks), fainting, elderly patients with hypertension have an increased risk of hemorrhagic stroke.

Immune system disorders: hives.

Skin and subcutaneous tissue disorders: skin rashes, itching, pale skin.

Other: galactorrhea, exacerbation of concomitant chronic diseases, asthenia (weakness).

Shelf life

3 years.

Do not use the medication after the expiration date printed on the package.

Storage conditions

Store out of the reach of children in the original packaging at a temperature not exceeding 25 °C.

Packaging

10 tablets per blister pack; 2 blister packs per package.

Sales Conditions

Available without a prescription.

Manufacturer

Darnitsa Pharmaceutical Company, PJSC.